Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EVZIO vs LORFAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Naloxone is an opioid antagonist that competitively binds to mu-opioid receptors, reversing opioid-induced respiratory depression and analgesia.
Lorlatinib is an ATP-competitive inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) tyrosine kinases. It inhibits phosphorylation of ALK and ROS1, leading to apoptosis and cell cycle arrest.
Emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.
FDA-approved for treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) in patients who have progressed on prior ALK inhibitors,Off-label: ROS1-positive metastatic NSCLC
2 mg intramuscular (IM) or subcutaneous (SC) autoinjector into anterolateral thigh; repeat every 2-3 minutes as needed for opioid overdose.
12 mg orally three times daily; titrate to 24 mg twice daily after 14 days based on response and tolerability.
The terminal elimination half-life of naloxone in adults is approximately 1-2 hours. In neonates, half-life may be prolonged to 3-4 hours. Clinical context: Short half-life necessitates repeated dosing or continuous infusion for sustained opioid reversal, especially with long-acting opioids.
Terminal elimination half-life is 2-3 hours in adults with normal renal function; prolonged in renal impairment (up to 20 hours in severe impairment).
Primarily hepatic glucuronidation, with N-allylnoroxymorphone as the major metabolite; CYP450 system not significantly involved.
Primarily metabolized by CYP3A4 and UGT1A4. Lorlatinib is a substrate of P-glycoprotein.
Naloxone undergoes extensive hepatic metabolism primarily via glucuronidation, with approximately 70% excreted in urine as naloxone-3-glucuronide. About 25% is excreted in feces via biliary elimination. Less than 1% is excreted unchanged in urine.
Primarily renal excretion (90-95% as unchanged drug); minimal biliary/fecal elimination (<5%).
Approximately 30-40% bound to plasma proteins, mainly albumin.
Approximately 20-30% bound to plasma proteins, primarily albumin.
Volume of distribution is approximately 2-3 L/kg, indicating extensive distribution into tissues beyond plasma volume. Clinical meaning: High Vd suggests rapid distribution and short half-life.
2.0-3.0 L/kg, indicating extensive distribution into tissues.
Intramuscular bioavailability is approximately 100% (assumed complete absorption). Oral bioavailability is <2% due to extensive first-pass metabolism; therefore, not used orally.
Subcutaneous: approximately 80-100%; intramuscular: approximately 80%; intravenous: 100%.
No dose adjustment required for renal impairment.
No adjustment required for GFR ≥ 30 m L/min; avoid use if GFR < 30 m L/min.
No dose adjustment required for hepatic impairment.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce to 12 mg once daily; Child-Pugh Class C: not recommended.
Weight-based: <20 kg: 0.1 mg/kg IM/SC; ≥20 kg: 2 mg IM/SC; repeat every 2-3 minutes if needed.
Not established for age < 18 years.
No specific dose adjustment; use standard adult dosing with monitoring for adverse effects due to potential comorbidities.
No specific dose adjustment; monitor renal function and tolerability closely due to age-related decline in renal function.
Risk of recurrent respiratory depression: The duration of action of naloxone is shorter than that of most opioids, so repeat doses may be necessary. Patients should be monitored until respiratory function is fully recovered.
None.
May precipitate acute opioid withdrawal in opioid-dependent patients; risk of incomplete response or need for repeat doses due to short half-life; not effective for non-opioid overdoses; avoid in known hypersensitivity; use caution in patients with cardiovascular disease or those taking cardiotoxic drugs.
Hepatotoxicity: Monitor liver enzymes monthly for first 3 months, then periodically.,Interstitial lung disease/pneumonitis: Withhold and evaluate.,Hyperlipidemia: Monitor serum cholesterol and triglycerides; manage with lipid-lowering agents.,CNS effects: Including seizure, hallucinations, cognitive impairment; dose adjust or withhold.,AV block: Monitor ECG; withhold in second- or third-degree AV block.,Fetal harm: Can cause fetal harm; advise effective contraception.
Hypersensitivity to naloxone or any component of the formulation.
Concomitant use of strong CYP3A4 inducers,Concomitant use of strong CYP3A4 inhibitors (avoid, or reduce dose if unavoidable)
None known; naloxone is not absorbed orally due to first-pass metabolism. No dietary restrictions.
Take on empty stomach with water only. Must follow a low-fat diet (<20% of total calories from fat) throughout treatment. Avoid grapefruit and grapefruit juice (CYP3A4 inhibition). Avoid alcohol due to hepatotoxicity risk.
EVZIO (naloxone) is not associated with major congenital malformations; limited data in pregnancy. Immediate reversal of opioid effects may precipitate withdrawal in the fetus, potentially causing adverse outcomes such as preterm labor or fetal distress. Third trimester use may cause neonatal opioid withdrawal syndrome (NOWS) in opioid-dependent mothers if naloxone is administered.
Lorlatinib is embryotoxic and fetotoxic in animal studies. In pregnant rats, malformations (including cardiovascular and skeletal) and fetal growth restriction observed at maternal exposures below human AUC. No human data. Avoid in pregnancy; if used, advise effective contraception.
Naloxone is unlikely to be excreted in breast milk in significant amounts due to low bioavailability. M/P ratio not established. Preterm infusion studies show minimal transfer. Consider benefits of breastfeeding against risk of maternal opioid overdose reversal.
No human data on lorlatinib in breast milk. Animal studies show excretion in rat milk. M/P ratio unknown. Due to potential for serious adverse reactions in nursing infants, advise not to breastfeed during treatment and for at least 11 days after last dose.
No pharmacokinetic studies in pregnancy demonstrate need for dose adjustment. Standard dosing (0.4 mg or 2 mg intranasal/IM) is used. Pregnant patients may require higher doses due to increased volume of distribution and metabolic changes, but evidence insufficient to recommend routine dose adjustment.
Physiologic changes in pregnancy (increased volume of distribution, enhanced hepatic metabolism) may reduce lorlatinib exposure. Monitor therapeutic response and toxicity. Consider dose adjustment based on tolerability (increase if subtherapeutic, but safety not established). No specific dose recommendations due to lack of human data; hold if severe toxicity.
EVZIO is a naloxone auto-injector for emergency treatment of opioid overdose. Administer intramuscularly or subcutaneously into outer thigh; can be given through clothing. Repeat every 2-3 minutes if no response. Onset of action within 2-5 minutes. Duration shorter than most opioids; monitor for recurrence of respiratory depression. Not for non-opioid overdoses.
LORFAN (lomitapide) is a microsomal triglyceride transfer protein inhibitor used for homozygous familial hypercholesterolemia. Monitor hepatic function monthly due to risk of elevated transaminases and hepatic steatosis. Must be taken with a low-fat diet (<20% of calories from fat) to reduce gastrointestinal adverse effects. Concomitant use with strong CYP3A4 inhibitors is contraindicated. Dose adjustments needed with moderate CYP3A4 inhibitors. Administer with water only, no food, at least 2 hours after evening meal and 2 hours before next meal.
Always call 911 immediately after giving EVZIO.,Place the device against the outer thigh and press firmly; it will automatically inject.,A short, clicking sound indicates the injection has started.,Stay with the person after injection; they may become agitated due to opioid withdrawal.,Store at room temperature; check expiration date regularly.,Tell family and friends where you keep EVZIO.
Take lomitapide with a low-fat diet; avoid high-fat meals to reduce stomach side effects.,Take the medication with a glass of water only, at least 2 hours after your evening meal and 2 hours before your next meal.,Do not eat grapefruit or drink grapefruit juice while taking this medication.,Inform your doctor immediately if you experience yellowing of eyes/skin, dark urine, or abdominal pain.,You will need regular blood tests to check liver function; do not miss these appointments.,Avoid alcohol consumption during treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EVZIO vs LORFAN, answered by our medical review team.
EVZIO is a Opioid Antagonist that works by Naloxone is an opioid antagonist that competitively binds to mu-opioid receptors, reversing opioid-induced respiratory depression and analgesia.. LORFAN is a Opioid antagonist that works by Lorlatinib is an ATP-competitive inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) tyrosine kinases. It inhibits phosphorylation of ALK and ROS1, leading to apoptosis and cell cycle arrest.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EVZIO and LORFAN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EVZIO is: 2 mg intramuscular (IM) or subcutaneous (SC) autoinjector into anterolateral thigh; repeat every 2-3 minutes as needed for opioid overdose.. The standard adult dose of LORFAN is: 12 mg orally three times daily; titrate to 24 mg twice daily after 14 days based on response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EVZIO and LORFAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EVZIO is classified as Category C. EVZIO (naloxone) is not associated with major congenital malformations; limited data in pregnancy. Immediate reversal of opioid effects may precipitate withdrawal in the fetus, pot. LORFAN is classified as Category C. Lorlatinib is embryotoxic and fetotoxic in animal studies. In pregnant rats, malformations (including cardiovascular and skeletal) and fetal growth restriction observed at maternal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.